pfizer post solid result provid slightli weak
guidanc share look under-valued
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
foundat remain solid base strong cash flow
gener basket divers drug compani larg size
confer signific competit advantag develop new
drug unmatch heft combin broad portfolio
patent-protect drug help build wide econom
moat around busi
size establish one largest economi scale
pharmaceut industri busi drug develop
need lot shot goal success financi
resourc establish research power support
develop new drug also mani year
struggl bring import new drug launch
sever potenti blockbust cancer heart diseas
commit postapprov studi provid
salespeopl armamentarium data market
campaign lead salesforc emerg
countri posit compani benefit dramat
increas wealth nation brazil russia india china
turkey
entrench industri leader face challeng
near term loss patent protect sever drug
weigh futur growth particular recent patent loss
viagra eventu patent loss lyrica
slow long-term growth
howev believ oper withstand
upcom gener competit acquisit wyeth
help insul one particular patent loss follow
merger much stronger posit vaccin
industri pneumococc vaccin prevnar vaccin tend
resist gener competit
manufactur complex rel lower price
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one world largest pharmaceut firm annual sale
billion also spend lead amount research
develop close billion annual histor sold mani
type healthcar product chemic prescript drug
vaccin account major sale top seller includ pneumococc
cardiovascular treatment eliqui immunolog drug enbrel xeljanz
sell product global intern sale repres
close total sale within intern sale emerg market
major contributor repres fifth total compani sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pfizer post solid result provid slightli weak
guidanc share look under-valued jan
report fourth-quart result slightli
consensu expect larg line
project guidanc slightli
consensu expect expect signific
fair valu estim chang weaker guidanc
partli due shift account invest
impact foreign exchang rate overal
continu view strong posit wide
econom moat bolster improv late-stag
quarter core portfolio post steadi gain
off-set gener competit lead total sale growth
rate expect declin slight posit growth
due larg patent loss neurolog
drug lyrica offset gener pressur strong
gain continu cardiovascular drug eliqui immunolog
drug xeljanz cancer drug ibranc intern
despit heavi competit drug
expect continu growth base excel efficaci
expand indic xeljanz ulcer coliti
ibranc adjuv set top product prevnar
slightli acceler result increas
strong progress make pipelin
lead faster growth sever new blockbust
reach market next two year remain
bullish cardiomyopathi drug tafamidi approv
like pain drug tanezumab approv like
atop dermat drug abrocitinib approv like
drug hold lead efficaci
potenti becom major blockbust
sever major drug midstag pipelin
reach market includ jak
inhibitor sever immunolog diseas
complet review pipelin current
report moat remain secur innov counter
price gener headwind acceler
increas fair valu estim per share
basi higher project rare-diseas
drug tafamidi look increasingli well posit
breakthrough statu grant
cardiomyopathi diseas associ progress
heart failur phase data drug drive
approv lead billion annual peak sale
look core busi expect annual
sale growth next three year
acquisit new drug off-set gener competit
howev bottom line project slightli healthier
annual growth rate next three year
cost-cut plan share buyback take shape
model unannounc acquisit acquisit hold
potenti acceler compani growth rate
long term believ diversifi line-up drug
reduc volatil earn anticip
restructur effort elimin duplic
posit help allevi margin pressur
high-margin product lose exclus cost capit
perspect estim cost equiti
weight averag cost capit line peer
larg base low volatil cash flow
divers product portfolio inelast demand rate
uncertainti low scenario analysi assum
base-cas fair valu estim bull-cas fair
valu estim probabl bear case
probabl project fair valu rel
base case scenario analysi show minor varianc
henc low uncertainti rate key factor affect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
eventu gener competit key drug also
pfizer oper structur allow cost-cut follow
patent loss reduc margin pressur lost
line creat enorm cash flow need fund
averag million develop cost per new drug
addit compani power distribut network
set compani strong partner smaller drug
compani lack resourc entrench
consum vaccin franchis creat ad layer
competit advantag stem brand power
consum healthcar manufactur cost advantag
vaccin divis consid sell
consum healthcar group potenti divest
materi impact compani moat
believ face stabl moat trend next
five year compani major patent loss repres
total sale howev strong pipelin
combin stabl current market drug lead
modest growth annual period
exclud acquisit also patent exposur
face biolog shouldnt declin fast
small molecul patent expir offset
patent loss pipelin side expect
billion peak annual sale three new drug includ
recent launch ibranc cancer pipelin drug
tanezumab pain ertugliflozin diabet
turn macroeconom environ
sever headwind make solid strateg move
address challeng neg side
risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
organ pharmaci benefit manag
consolid past decad use
grow size demand lower drug price reduc
scenario analysi includ degre success
brand drug pipelin along magnitud market
pressur current market drug within group
recent launch drug import driver
valuat ibranc cancer addit unknown
magnitud biosimilar competit
immunolog diseas weigh certainti
enbrel
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
competit aris addit hold
diversifi product portfolio
product
concentr compani largest product prevnar
repres total sale howev
expect typic gener competit vaccin due
complex manufactur rel low price
product expect new product mitig
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
coverag less innov drug forc drug firm
push true innov reduc power pfizer
distribut network govern
evalu compar effect program
aggress price negoti rais bar futur
innov face sever headwind
pipelin focus innov treatment area
unmet medic area cancer payer
coverag price power remain strong outsid
pipelin compani strong entrench vaccin
consum healthcar give firm relief
pressur drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pipelin product improv sever
potenti game-chang immunolog
major
blockbust breast cancer
ibranc develop
oth stock support dividend yield
expect steadi cash flow support dividend
owhil decid break compani
innov core establish drug group
increas visibl segment option
revisit decis creat potenti futur valu
research
late-stag pipelin look strong enough
drive robust growth
oalthough compani worst
patent cliff still face recent major patent loss
viagra futur one lyrica
osever late-stag pipelin drug
enter crowd market may limit share gain
due delay entri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
hold strong financi posit larg
degre flexibl end debt/capit
stood debt/ebitda ratio
suggest remain solid financi foot
major cash flow deriv divers portfolio
product dont expect high degre volatil
futur earn like continu make
acquisit believ rel easili take debt
fund larger deal
face gener competit increasingli stringent
fda stronger managed-car pharmaci benefit
manag negoti power new drug develop
becom challeng sever diseas area
pharmaci benefit manag grown past
two decad power entiti negoti lower
drug price although remot litig risk remain
evidenc merck high settlement cost involv
vioxx also sever pipelin drug reach
market behind competitor may increas risk
commerci failur put downward price
pressur drug clinic data lack posit
differenti brand competit front merck
work develop next-gener pneumococc
vaccin cover valent could threaten
prevnar cover two fewer valent howev
overal view uncertainti low base
low volatil cash flow divers product portfolio
inelast demand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
rate stewardship standard
compani made mani poor capital-alloc decis
past decad current manag team
appear focus significantli better use cash
includ share buyback dividend also decis
sell nutrit anim healthcar busi
appear creat valu sharehold
front acquisit hospira strengthen
moat establish drug segment price look
reason howev high price paid mediv
fail attempt acquir astrazeneca allergan
concern
surpris move name longtim veteran
ian read ceo post abruptli replac jeffrey kindler
believ earlier-than-anticip departur kindler
larg due person reason believ
transit rais red flag read bring
year experi post
recent charg compani biopharmaceut
busi ceo read brought stamp post
signal strong willing cut buy back
share believ read leadership bring chang
need increas compani growth potenti
report side account transpar ideal larg
financi distort caus frequent
acquisit reconcili gener accept
account practic result adjust result
complex dilut clariti earn statement
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
glaxo pfizer consum joint ventur creat
synergi unlock underli valu dec
glaxosmithklin announc creation
consum healthcar joint ventur follow potenti
separ entiti expect drive better
synergi unlock valu compani
expect signific chang fair valu estim
either compani compani expect close gbp
cost synergi seem reason
addit believ potenti separ new
joint ventur could unlock valu glaxo
consum healthcar compani trade higher valuat
multipl pharma firm time
transact fulli clear format joint
ventur complet second half
separ joint ventur could happen two
moat standpoint joint ventur would boast
strong brand power annual sale close gbp
billion well-known product theraflu excedrin
advil centrum expect robust brand power
support strong competit advantag new entiti
addit expect potenti separ
joint ventur glaxo affect moat
remain firm drug vaccin oper
consum product contribut smaller amount profit
overal compani dis-synergi perspect
potenti separ consum entiti would eras
financi benefit prescript over-the-count
switch success drug like
like separ consum entiti glaxo
expect capit shift back drug
compani ipo ad debt consum
unit spin-out expect drug firm use
capit acquir smaller firm mid- late-stag drug
develop area unmet medic need
post larg in-lin recent launch
report third-quart result larg line
consensu expect littl soft
top line littl strength bottom line
make signific chang fair valu
base result addit bottom-lin strength
partli support stronger incom
view fundament driver growth
compani rather line use one-tim item
overal larg in-lin quarter reinforc current
valuat close market price
turn compani wide moat continu view
compani strong competit posit result
reinforc compani strength recent launch
drug offset patent pressur older drug total sale
quarter increas oper support
strong growth cardiovascular drug eliqui cancer drug
ibranc immunolog drug xeljanz offset gener
competit older drug expect growth
driver deceler next three year ibranc
continu grow rapidli intern market
adjuv indic reacceler growth
also eliqui continu take share
older inferior drug warfarin still hold
addit late-stag pipelin set
compani steadi growth next three year
expect new blockbust drug sale billion
annual includ pain drug tanezumab vyndaqel
cardiomyopathi extend compani
pneumococc vaccin franchis two jak inhibitor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
immunolog diseas
late-stag drug look well posit off-set
key patent loss next three year includ
 patent loss neurosci drug lyrica
complet review ngf market outlook
tanezumab pleas see report pain potenti
lot lilli regeneron also report
lilli regeneron address unmet need chronic pain
market provid insight thoma schnitzer md phd
outlook ngf class
overal strategi oct
follow announc name albert bourla
new ceo effect jan expect
chang fair valu estim wide moat rate
continu view stock modestli under-valued
pipelin like fulli appreci
announc bourla move top spot signal
like continu strateg focu move
toward area unmet medic need drug develop
divest asset area lack scale make
synergist mid-size acquisit guid
continu steadi growth bourla background
chief oper offic well leadership
innov drug busi give strong credenti
run overal organ believ gain
spot januari larg set eventu ceo
appoint thought telegraph passag
leadership welcom pathway contrast past
ceo chang ian read abruptli took
follow increas concern previou ceo
bourla probabl want leav mark
legaci expect calm hand helm similar read
decis made calcul way best interest
sharehold patient
pharma moat outlook compani still strong
analysi pharma compani continu
see industri well posit strong econom
moat analysi reaffirm moat
rate increas bayer moat wide
narrow bayer divestitur materi scienc group
combin strong drug busi well-posit
bolster monsanto
acquisit led us upgrad moat rate wide
moat pharma compani
increas focu innov area unmet medic
need enabl strong price power off-set increas
negoti power pharmaci benefit manag
 restrict price develop market outsid
 drug carri patent protect allow firm
charg near monopolist price drug true price
power determin sever factor includ benefit
patient uniqu govern outsid
 pbm within increasingli push
back drug price medicin lack signific
benefit overal stronger drug uniqu
efficaci stronger drug price power result
major drug compani focus
develop effort area signific unmet medic
addit segment within pharma firm anim
health consum healthcar carri strong moat
augment moat strength deriv human brand
drug segment overal moat analysi guid
under-valued call bayer glaxosmithklin
valuat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rate improv tafamidi use third
patient
drug option avail attr-cm
alnylam onpattro approv anoth relat rare
diseas polyneuropathi hereditari attr strong
efficaci onpattro
all-caus
hospit mortal may drive off-label
usag drug directli tafamidi expect
off-label competit limit
complet overview pipelin pleas see
threat secur pharma moat
complet overview pharma moat analysi
pleas see report pharma moat outlook compani
still strong posit analyz key point
around moat larg pharmaceut industri
post strong rare-diseas drug data lead
report posit phase data rare-diseas drug
tafamidi transthyretin amyloid cardiomyopathi attr-
cm lead increas annual peak tafamidi
project billion million also
increas fair valu estim per share
continu believ under-valued view
strong tafamidi result good exampl
matur pipelin strengthen futur cash flow
reinforc compani wide moat
peak tafamidi sale project base strong
efficaci limit treatment option like strong price
power phase data show reduct all-
caus mortal drive strong util
drug favor reimburs preval
diseas limit estim
peopl develop market
accord believ less diagnosi
rate show like difficulti reach patient
howev without approv drug patient
popul histor believ
motiv diagnos diseas also limit
patient size combin strong efficaci enabl
strong price least annual even
account value-bas price rare-diseas
drug util overal project chanc
approv base strong efficaci benign side effect
profil long term expect diagnosi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
